30 closest matches · ranked by relevance
Brain Diseases, Metabolic, Inborn · Urea Cycle Disorder · Ornithine Transcarbamylase Deficiency
Primary: Concentration of Glutamine and Myoinositol by MRS — 4.97; 3.66; 3.78; 4.50 mM — p=0.003
Conversion Disorder
Primary: Gray Matter Volume Biomarkers of 6 Month Prognosis as Measured by Voxel Based Morphometry - Within Group Comparison — 4.18; 3.27; 3.85; 3.76 peak voxel z-score
Alzheimer Disease · Presbycusis · Lexical Syntactic Disorder
Primary: Link Between Lack of Word and Presbycusis — 38; 38.5; 23; 21.5 score on a scale
Multiple Sclerosis · Chronic Pain · Neurological Disorder
Primary: Change in Patient-Reported Outcomes Measurement Information System (PROMIS) - Pain Intensity - Short Form 3a Score — 0.42 score on a scale
Metastatic Brain Tumor · Primary Brain Tumor · Epileptic/Seizure Foci
Primary: Safety (Reportable Adverse Events) — 1; 7; 2; 30 Participants
Neurofibromatosis Type 1 · Reading Disabilities
Primary: Change From Baseline in WJ-III Basic Reading Normative Update (Woodcock Johnson Psychoeducational Battery - 3rd Edition; WJ-III NU) Standard Score at 15 Hours — 13.50…
Epilepsy · Tumor · Healthy
Primary: Localizing Brain Regions That Generate Interictal Spikes — 52 Participants
Neurofibromatosis 1
Primary: Mitochondrial Respiration Efficiency (as Measured by OCR). — 67.7167; 53.7000; 73.3358; 68.5789 picomole/minute — p=<0.01
Nonconvulsive Status Epilepticus · Subclinical Seizure · Altered Mental Status
Primary: Time Difference Between EEG Cap and Standard EEG Results Reporting — 103.4 minutes — p=0.0005
Amyotrophic Lateral Sclerosis · Parkinson Disease · Dysphagia
Primary: Number of Participants With Residue of Concern (Observational) — 6; 6; 3; 6 Participants
Phenylketonuria
Primary: Phenylalanine Level in the Brain as Determined by MR Spectroscopy and in Blood — 130; 137; 961 umol/L
Neurofibromatosis 1
Primary: Change From Baseline in Motor Function Measured by Physical and Neurological Examination for Subtle Signs (PANESS) — 0; 3 score on a scale
Anxiety · Depression
Primary: Reaction Time to Facial Affect Identification During Emotional Conflict — 802.15; 889.14; 848.79; 937.97 milliseconds — p=0.004
Non-verbal Learning Disorder · Autism Spectrum Disorder · Autism
Primary: Mean Change in the Parent-Young Mania Rating Scale (P-YMRS) Score — 0.0; -2.6 Units on a Scale
Schizophrenia · Traumatic Brain Injury
Primary: Mismatch Negativity (MMN) Amplitudes in Microvolts — -0.59; -1.19; -0.41; -0.65 microvolts
Ornithine Transcarbamylase Deficiency
Primary: Concentration of Glutamine and Myoinositol — 2.61; 1.66; 2.23; 2.69 mM — p=0.001
Parkinson Disease · Idiopathic Parkinson Disease
Primary: Distribution Volume Ratio — 2.65; 2.70; 2.96; 2.74 Distribution volume ratios — p=0.05
Schizo-affective Disorder · Bipolar Disorder
Primary: Positive and Negative Symptom Scores at Baseline and at 2 Weeks, 4 Weeks, and 6 Weeks During Intervention 1 (Glycine or Placebo), Intervention 2 (Glycine or Placebo)…
Parkinson's Disease
Primary: Unified Parkinson Disease Rating Scale (UPDRS). — 12; 12; 10; 10 units on a scale
Alzheimer Disease · Neurodegenerative Diseases
Primary: Alpha-synuclein Levels From Nasal Swabs
Orthostatic; Hypotension, Neurogenic
Primary: Change in Orthostatic BP Drop — 11.1; 13.6; 8.9; 7.5 mmHg
Brain Injury
Primary: Change From Baseline on a Composite Measure (Z-score) of Attention, Working Memory, and Executive Functions — 0.26; .01 Change to Z (composite) score
Symptomatic Neurogenic Orthostatic Hypotension (NOH) · Non-diabetic Neuropathy · Primary Autonomic Failure
Primary: Change in Orthostatic Hypotension Questionnaire Score (OHQ) — -1.83; -0.93 units on a scale — p=0.003
Symptomatic Neurogenic Orthostatic Hypotension (NOH) · Non-diabetic Neuropathy · Primary Autonomic Failure
Primary: Change in Dizziness/ Lightheadedness/ Feeling Faint/ or Feeling Like You Might Blackout (OHSA Item 1) — 1.3; 1.9 units on a scale — p=0.509
Chronic Troublesome Sialorrhea · Cerebral Palsy · Stroke
Primary: Change From Baseline in Unstimulated Salivary Flow Rate (uSFR) at Week 4 — -0.07; -0.14 gram per minute (g/min) — p== 0.0012
Diabetes Mellitus · Polyneuropathies · Arthropathy, Neurogenic
Primary: Induration Size as a Response to Intracutaneous Candida Albicans. — 4; 6; 5; 4 millimeters — p=0.84
Parkinson Disease
Primary: Number of De-novo Patients in Whom Monotherapy With Mirapexin® Could be Successfully Initiated — 403; 323; 73; 15 Participants
Cerebral Palsy
Primary: Change in Walk Dynamic Motor Control Index 6-months After Orthopaedic Surgery — -2.4 normalized z-score
Primary Autonomic Failure · Dopamine Beta Hydroxylase Deficiency · Non-Diabetic Neuropathy
Primary: Patients With Treatment-emergent Adverse Events — 263 participants
Healthy
Primary: Oculo-Cognitive Addition Test (OCAT) Completion Time — 57.22; 57.22; 59.56; 58.18 seconds